Dual diagnosis treatment for Delray Beach — one team, both diagnoses, together.

RECO Health's flagship campus at 140 NE 4th Avenue sits one block off Atlantic Avenue, walkable from Pineapple Grove and the Beach District. Dual diagnosis care is delivered by one clinical team: a single in-house psychiatrist manages both MAT and psychotropic medication, and the same therapists hold the addiction and psychiatric work on one integrated plan. For Delray Beach residents, evidence-based care requires no relocation.

RECO Health’s flagship campus at 140 NE 4th Avenue sits one block off Atlantic Avenue in Delray Beach, a short walk from the ocean and inside the daily footprint of Pineapple Grove, Lake Ida, Tropic Isle, the Beach District, and Osceola Park. For local residents, integrated addiction and psychiatric care does not require relocation, an interstate flight, or a severed community. Substance use disorder and co-occurring psychiatric illness are treated on a single coordinated plan rather than parceled out across disconnected providers.

Why sequential treatment fails for co-occurring disorders

The clinical literature on sequential care is unambiguous. The “get sober first, then we’ll address the mental health” model produces measurably worse outcomes than integrated treatment across nearly every endpoint that matters: relapse rates, psychiatric hospitalization, treatment retention, and suicidality. The untreated diagnosis destabilizes the treated one. Depression left unaddressed during a substance use admission drives early relapse; unmanaged substance use during a psychiatric admission blocks antidepressant response and inflates acute risk.

Integration is not a philosophical preference. It is the standard of care articulated by SAMHSA, NIDA, and the American Psychiatric Association. Delivering it requires clinical staff dually credentialed in addiction and psychiatric medicine: a psychiatrist who prescribes both buprenorphine and lithium without deferring one to an outside provider, therapists who hold CBT for depression and relapse-prevention work inside the same treatment plan, and case management that coordinates rather than fragments.

The high-prevalence co-occurring diagnoses

Roughly half of adults with a substance use disorder meet criteria for at least one concurrent psychiatric condition. Major depressive disorder, PTSD, generalized anxiety disorder, bipolar spectrum disorders, and adult ADHD dominate that population. RECO screens all five at intake with validated instruments: PHQ-9 for depressive symptoms, PCL-5 for PTSD, GAD-7 for generalized anxiety, MDQ for bipolar screening, and ASRS for adult ADHD. YBOCS is added when OCD-spectrum symptoms surface during the psychiatric evaluation.

Each diagnosis carries a defined evidence-based pathway inside the program. Depression is treated with an SSRI or SNRI (sertraline, escitalopram, or venlafaxine as first-line) combined with cognitive behavioral therapy and behavioral activation, with esketamine or ketamine considered for treatment-resistant presentations. PTSD is treated with cognitive processing therapy, prolonged exposure, or EMDR, sequenced against the client’s window of tolerance. Bipolar disorder is stabilized on lithium, lamotrigine, or an atypical antipsychotic such as quetiapine or aripiprazole before deeper therapy content begins. ADHD is managed with non-stimulant agents such as atomoxetine or guanfacine or, when clinically appropriate and closely monitored, a stimulant regimen with attention to substance-use history.

MAT and psychotropic medication managed by one psychiatrist

Fragmented prescribing across a primary care physician, an outside psychiatrist, and a separate MAT clinic is one of the most common structural drivers of relapse in this population. At RECO, a single in-house addiction psychiatrist manages the client’s dual diagnosis treatment pharmacology end to end. Buprenorphine or extended-release naltrexone for opioid use disorder, naltrexone or acamprosate for alcohol use disorder, and the client’s antidepressant, mood stabilizer, anxiolytic, or ADHD medication are prescribed by the same clinician on the same visit.

That structure lets the prescriber flag interactions in real time: QT-prolongation risk when combining methadone with certain antidepressants, sedation risk when pairing quetiapine with a partial opioid agonist, or hepatic considerations for a client on naltrexone with elevated LFTs. Dosing is coordinated against ASAM Criteria level of care and titrated as the client moves through detox, residential, PHP, and IOP without a handoff between prescribers.

Trauma is often the through-line

For a substantial share of dual diagnosis clients, unresolved trauma sits upstream of both the substance use and the mood or anxiety disorder. Screening at intake includes the PCL-5 and a full trauma history inventory; positive screens are followed by a formal clinical trauma assessment during the first treatment week. Early phase focuses on stabilization: sleep, nutrition, medication response, and skills work in DBT and ACT to widen the window of tolerance before any exposure-based intervention begins.

Trauma processing (cognitive processing therapy, prolonged exposure, or EMDR) begins only when the client is medically stable and psychologically resourced. Attempting exposure work with an acutely dysregulated client can retraumatize; deferring it indefinitely produces early sobriety and late relapse. RECO’s protocol sequences the two deliberately so that trauma is addressed rather than avoided, and so that the substance use is not left as the client’s only remaining coping strategy.

What to expect on the first visit

An admission from Delray Beach typically starts with a phone screen the same day the client or family calls. Insurance is verified inside an hour, medical necessity is established, and an arrival window is set. If medical detox is indicated, CIWA-Ar drives alcohol withdrawal management with symptom-triggered chlordiazepoxide or lorazepam; COWS drives opioid withdrawal management with buprenorphine induction per SAMHSA guidance. If detox is not required, the client moves directly into residential or PHP intake.

Day one includes a full biopsychosocial history, ASAM Criteria assessment across all six dimensions, psychiatric evaluation with the in-house psychiatrist, physical exam, and medication reconciliation covering both MAT and psychotropic prescriptions. The primary therapist is assigned within 72 hours, and the multidisciplinary team meets to finalize the integrated treatment plan before the end of the first week. For clients whose depression is treatment-resistant, rTMS (typically 3000 pulses per session at 120% of motor threshold) or ketamine services are evaluated during the psychiatric workup.

Insurance and admissions from Delray Beach

RECO’s Delray Beach campus is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and other BCBS plans for the full continuum: detox, residential, PHP, and IOP. Admissions runs benefits verification during the initial call, typically inside an hour, and reviews deductibles, coinsurance, and out-of-pocket exposure with the client before admission is confirmed. Out-of-network plans and single-case agreements are handled routinely.

For residents of Pineapple Grove, Lake Ida, Tropic Isle, the Beach District, and Osceola Park, the campus at 140 NE 4th Avenue is walkable or a five-minute drive from most of central Delray. When clients step down from residential to PHP and IOP, the same clinical team carries the treatment plan forward. Continuity, not handoff, is the operating model, and it is the reason the outcomes data from integrated care remains more durable than the alternative.

Serving residents of: Pineapple Grove, Lake Ida, Tropic Isle, Beach District, Osceola Park.